Introduction
Over recent decades, small nucleic acids, such as antisense oligonucleotides (ASO) and small interfering RNA (siRNA), have been extensively highlighted as potential drugs for treatment of various intractable diseases, including cancer (1) (2) (3) . This is because they can regulate the expression of disease-related genes with high target sequence specificity. However, the arrival rate of exogenous nucleic acids from the injected site to the target cell cytoplasm or nucleus, i.e., bioavailability, is substantially low, mainly due to their high susceptibility to enzymatic degradation, and negatively charged macromolecular structures that impede passive diffusion into the cytoplasm across the cell membrane. These obstacles have hampered the translation of nucleic acid-based drugs into pharmaceutical products.
To overcome the poor bioavailability of nucleic acids, various methodologies have been explored. Chemical modifications of the nucleotide backbone are one of the most typical approaches for stabilization of nucleic acids in biological fluids with reduced immune responses (2) . Indeed, the clinically approved ASOs, fomivirsen and mipomersen, are composed of a phosphorothioate backbone, and the approved RNA aptamer, pegaptanib, contains 2'-F and 2'-O-methyl modifications (2) . These backbone modifications not only protect nucleic acids from enzymatic degradation, but also affect their biodistribution and cellular uptake profiles. For instance, phosphorothioate-modified ASOs are reported to bind to plasma proteins in the bloodstream, leading to enhanced accumulation in the liver (4) .
A more direct approach for improving the biodistribution and cellular uptake profiles of nucleic acids is to combine them with delivery molecules. Of these, the simplest formulation is a nucleic acid conjugated to a ligand molecule that can bind to a specific molecule (or receptor) on the target cell surface ( Figure 1A ) (5) . One of the most successful examples is siRNA conjugated with N-acetyl-D-galactosamine (GalNAc), which targets the asialoglycoprotein receptor (ASGPR) expressed on the hepatocyte surface (6) . This formulation is undergoing a phase III clinical trial (3) . Another major formulation is poly(ethylene glycol) (PEG)-coated (PEGylated) nanoparticles ( Figure  1B ), which can be fabricated by the self-assembly of negatively charged nucleic acids and cationic lipids or polycations bearing PEG chains (7, 8) . In this formulation, the nanoparticle core can protect nucleic acid payloads from enzymatic degradation and the PEG shell can suppress nonspecific protein adsorption through the steric repulsion effect, permitting the longevity of nucleic acids in harsh in vivo conditions. Notably, PEGylated nanoparticles with a size of several tens of nanometers can preferentially accumulate in solid tumors through leaky tumor vasculature, which is termed the enhanced permeability and retention (EPR) effect (9, 10) , following systemic administration. Indeed, several formulations of anticancer drug-loaded PEGylated nanoparticles are clinically approved or undergoing clinical trials (11) (12) (13) . It should be also noted that targeting ligand molecules can be installed onto the surface (or the PEG terminus) of PEGylated nanoparticles, generating a multivalent binding effect for enhanced target recognition (8, 11) .
Among the structural components of PEGylated nanoparticles, block copolymers comprising PEG and polycation segments are highly appealing because they can be readily functionalized by chemical modification to create multifunctional polymeric nanocarriers (7, 14) . In particular, biological environment-responsive chemistries, including redox potential-and pH-sensitive linkages, enable block copolymers to generate "smart" polymeric nanocarriers that can exhibit the desired delivery functions, such as reversible stability, targeting ability, and endosome-escaping ability, in response to a specific biological environment or signal. The present review describes the design of smart polymeric nanocarriers and recent progress toward systemic nucleic acid delivery mainly to solid tumors.
Biological barriers in nucleic acid delivery
Prior to the structural design of block copolymers, this chapter describes the biological barriers to nucleic acid delivery, as well as the prerequisites for nucleic acid-loaded nanocarriers. As illustrated in Figure 2 , nucleic acid delivery is divided into two major stages: to the extracellular milieu, and into the intracellular compartment. In the case of systemic administration, nanocarriers need to stably circulate in the bloodstream without disintegration or distribution into non-target organs/tissues. It is known that relatively small macromolecules (or nanocarriers) with a molecular weight (MW) of less than ~40,000 (or a diameter of less than ~8 nm), e.g., naked ASO and siRNA, are rapidly cleared from the bloodstream via renal excretion (15, 16) . On the other hand, strongly charged larger macromolecules (or nanoparticles) are more likely to be entrapped by the reticuloendothelial system (RES) via nonspecific protein adsorption, leading to their clearance from the blood (7). Thus, nanocarriers ideally have a size of over ~10 nm with a nonionic and hydrophilic (or biologically inert) surface, i.e., a PEG shell, to maintain longevity in the bloodstream.
At the target organ/tissue, nanocarriers need to extravasate from the bloodstream. In the case of solid tumors (or inflammatory tissues), the vascular pores are relatively large with sizes of > 100 nm, allowing nanocarriers with a size of < 100 nm to extravasate toward the tumor tissue. This is known as the EPR effect (9, 10) . Meanwhile, the size of vascular pores in healthy organs/tissues, except for the liver and spleen, is less than 10 nm, and thus, active transport mechanisms, e.g., transcytosis, may be required for nanocarriers targeting healthy organs/tissues with smaller vascular pores. After extravasation or in the case of local administration, nanocarriers need to deeply permeate the target tissue to access a wide range of target cells. Tumor tissue permeability of nanocarriers is substantially affected by tumor heterogeneity or histological characteristics (17, 18) . When a series of anticancer drug-loaded nanocarriers with varying sizes of 30, 50, 70, and 100 nm were intravenously administered into subcutaneous tumorbearing mice, their tumor accumulation profiles were dramatically altered according to the tumor model. In the case of a hypervascular colon (C26) tumor model, all the nanocarriers showed similar, efficient tumor accumulation (~10% dose/g tissue) ( Figure 3A ) (18) . In contrast, in the case of a thick fibrotic, hypovascular pancreatic (BxPC3) tumor model, the smaller nanocarriers more efficiently accumulated in the tumor tissue, compared with the larger ones, associated with The first section focuses on the basic properties of polymeric nanocarriers prepared with PEG-polycation block copolymers. The following sections highlight the functionalization of block copolymers to improve the delivery of polymeric nanocarriers.
Basics of block copolymer self-assembly
When PEG-polycation block copolymers are mixed with nucleic acids in aqueous solutions, they can spontaneously assemble into polyion complexes (PICs) through charge neutralization. This PIC formation can be explained by a two-step assembly process, as illustrated in Figure 4A (19) . The primary step forms a minimal charge-neutralized polyion pair between a PEG-polycation and a nucleic acid, termed a unit PIC (uPIC). Above a critical association concentration (CAC), uPICs undergo secondary assembly into micellar PICs (mPICs). This two-step self-assembly is clearly demonstrated when single-strand RNA (ssRNA) (21-mer) is combined with PEG-poly(Llysine) (PEG-PLys) (MW of PEG (MW PEG ): 12,000, degree of polymerization of PLys (DP PLys ): ~40) ( Figure  4B ) (20) . At lower concentrations (< 0.01 mg/mL), the formation of small PICs with a hydrodynamic diameter (D H ) of ~10 nm is clearly observed, corresponding to the primary assembly step, i.e., uPICs. In contrast, the D H value is obviously increased at concentrations greater than 0.01 mg/mL, ultimately reaching ~40 nm. The transmission electron microscopic (TEM) image of PIC samples prepared at higher concentration displays the spherical nanoparticles ( Figure 4C ). These results demonstrate the formation of micelles from uPICs through the secondary assembly step. Meanwhile, a large difference is observed for double-strand RNA (21-mer/21-mer), i.e., siRNA, which maintains the uPIC structure without progressing to secondary an apparent size threshold of ~50 nm ( Figure 3B ) (18) . These results strongly suggest that smaller nanocarriers with a size of < 50 nm are more suitable for deep permeation within heterogenous tumor environments.
After reaching the target cells, nanocarriers need to migrate to the cytoplasm (or nucleus) by overcoming cellular barriers, namely the cytoplasmic membrane and the endosomal membrane (and nuclear membrane if the target site is the nucleus). Nanocarriers are generally uptaken by cells via adsorptive endocytosis (4, 14) . Thus, stronger binding affinity to the target cellular surface is likely to result in more efficient cellular internalization of nanocarriers. However, a stronger binding ability conflicts with the biological inertness derived from the PEG shell that allows for avoiding RES entrapment as well as nonspecific protein adsorption. To overcome this conflicting issue, the so-called PEG dilemma, the PEG shell can be further modified with a targeting ligand molecule for more specific binding, as aforementioned. Otherwise, the PEG shell can be designed to disintegrate from the nanocarrier by utilizing cleavable linkages at the target site. After endocytosis, nanocarriers are generally subjected to endosomal sorting toward lysosomal digestion, and thus, they must escape from the endosomal compartment into the cytoplasm, where the nucleic acid payloads must be released from the nanocarrier to access the gene silencing machinery, hybridize with the complementary messenger RNA, or form the RNA-induced silencing complex (RISC).
Design of block copolymers for nucleic acid delivery
This chapter describes the design of block copolymers for construction of smart polymeric nanocarriers, especially for systemic siRNA delivery to solid tumors. The polymeric micelles were prepared from a platinum anticancer drug, 1,2-diaminocyclohexane-platinum(II), and a mixture of PEGpoly(glutamic acid)/homo-poly(glutamic acid) to produce varying hydrodynamic diameters. A subcutaneous tumor model was developed using a colon cancer cell line, C26 (A), and a pancreatic cancer cell line, BxPC3 (B). These results were originally reported in reference 18. assembly even at much higher concentrations ( Figure  4B ). This difference may be explained by the difference in rigidity (or persistence length) between ssRNA and siRNA. siRNA has a persistence length of 60 nm, thereby being considered as having rigid cylindrical architecture. This rigidity potentially compromises the entropy gain that is associated with secondary assembly (or segregated core formation in a micelle), compared with flexible ssRNA with a persistence length of 1 nm, and hence inhibits mPIC formation. These results suggest that additional association forces of siRNAloaded uPICs are crucial for construction of stable siRNA-loaded mPICs.
mPICs have a core-shell architecture, wherein the PEG shell comprises the biologically inert (or biocompatible) surface and can be further modified with ligand molecules for preferential accumulation in target tissues/cells ( Figure 4A ). The D H of oligonucleotideloaded mPICs prepared from PEG-PLys is reported to range from 40 to 80 nm with a narrow size-distribution (polydispersity index in dynamic light scattering, µ2/ Γ 2 < 0.1) (21, 22) . The smaller mPICs were constructed using PEG-PLys with shorter PLys segments, e.g., DP PLys = ~20 and ~40, whereas PEG-PLys with a longer PLys segment (DP PLys = ~80) generated the larger mPICs (20, 22) . Thus, the smaller mPICs are potentially highly efficient for permeation within solid tumor tissues, in contrast with lipid nanoparticles with a D H of ~90 nm (23) .
To fabricate more stable mPICs, the polycation segment in block copolymers can be modified with stabilizing units. In PEG-PLys, the modification of primary amines in the PLys segment with a guanidino group significantly enhances the stability of siRNAloaded mPICs, possibly due to the hydrogen bonding (24) . Additionally, hydrophobic groups, such as cholesteryl groups and stearoyl groups, or hydrophobic polymer segments, can be introduced into the side chains or the ω-end of the polycation segment in block copolymers for stabilization of the mPIC through hydrophobic interactions ( Figure 5 ) (25) (26) (27) . Conversely, hydrophobic modifications can also be applied to nucleic acids instead of the polycation segment; cholesterol-modified siRNA allowed for preparation of more stable mPICs compared with non-modified siRNA (28) . As another stabilizing approach, mPICs can be coated with an additional outer layer, such as silica gel, which is readily prepared by simply mixing mPICs with silicate ions (29) . 
Polymer design for reversible stability
Whereas nanocarriers need to stably encapsulate nucleic acid payloads in extracellular milieu, they must ultimately release the payloads for effective gene silencing at the target site of action. To fulfill this apparently conflicting demand, block copolymers and their polymeric nanocarriers can be functionalized by environment-responsive chemistry for reversible stability or programmed payload release. Among various biological parameters, redox potential and pH have been most extensively utilized to trigger an environmental response from block copolymers because their levels are drastically altered between the interior and exterior of the cell. The cytoplasm is known to be a reductive environment, as the concentration of reduced glutathione (GSH), which acts as a reductive agent in the body, is three orders of magnitude higher in the cytoplasm compared with the extracellular milieu (30) . Accordingly, reductive environment-responsive disulfide bonds can be utilized for stabilization of mPICs by cross-linking the polycation segments (24, 28, (31) (32) (33) (34) (35) (36) . In this way, the disulfide cross-linked mPICs can be stabilized in non-reductive conditions, while they are destabilized through the cleavage of disulfide bonds in reductive conditions, resulting in accelerated payload release in the cytoplasm ( Figure  6A) . Similarly, the pH in the late endosome (pH ~5.5) is known to be significantly lower than pH in the extracellular milieu (pH 7.4) and the cytoplasm (pH 7.2) (37). Therefore, cross-linking via acid-labile bonds, such as an acetal group (38) , is also useful for the fabrication of acidic pH-responsive nanocarriers that can preferentially release payloads within the late endosome.
Although previous studies have reported a certain extent of stabilization from disulfide cross-linking, the stability of siRNA-loaded mPICs in the bloodstream still requires improvement, as the blood half-life is reported to be ~10 min (33, 34) . This limitation in the longevity of siRNA-loaded mPICs may be due to significant leakage of siRNA payloads from the crosslinked polycation network in the mPIC. This leakage hypothesis is supported by fairly high stability of the mPICs, with cross-links formed between polycation and polyanion segments, allowing for a blood half-life of ~5 h (39) . This fact suggests that direct conjugation of siRNA with the polycation segment via reversible linkages may be a promising strategy for increasing the longevity of mPICs in the bloodstream. To this end, a previous study highlights the characteristic moiety of siRNA, namely the cis-diol in the ribose ring at the 3' end of siRNA. The cis-diol group can make a reversible ester bond with tetravalent phenylboronic acid (PBA) groups. Accordingly, siRNA with cis-diol groups can act as a cross-linker between PBA-modified polycation segments through phenylboronic ester bonding, thereby generating the siRNA-mediated cross-linked mPICs ( Figure 6B ). Notably, this phenylboronic ester bond can be replaced with the cis-diol group contained in adenosine triphosphate (ATP) in a concentrationdependent manner (40) . Particularly, whereas the mPICs cross-linked with siRNA were stable at low ATP concentrations of < 1 mM, high ATP concentrations of > 2 mM dramatically accelerated siRNA release from the mPICs. Considering that the extracellular and intracellular ATP concentrations are ~0.4 mM and 3 mM, respectively (41), these siRNA-mediated cross-linked mPICs are expected to selectively release the siRNA payloads in the intracellular compartment ( Figure 6B ), which is currently under investigation. On the other hand, the siRNA-mediated cross-linked mPICs achieved a blood half-life of > 60 min (unpublished data), demonstrating the strong potential of direct conjugation of nucleic acids to polycation segments for increasing the longevity of polymeric nanocarriers in the bloodstream.
Polymer design for active targeting and facilitating cellular uptake
After extravasation from the vessel into the target tissue, nanocarriers should ideally enter the target cells efficiently. In this regard, the PEG shell of mPICs significantly suppresses their cellular internalization through the steric repulsion effect (PEG dilemma). One of the most promising approaches to overcome this dilemma is active targeting using ligand molecules. Indeed, a variety of ligand molecules, including GalNAc, can be installed onto the nanocarrier surface, as reviewed elsewhere (8, 42) . In this way, multiple ligand-installed nanocarriers permit multivalent binding to target cellular surfaces for enhanced target recognition, which is in sharp contrast with the single ligand-mediated monovalent binding. As a representative ligand, transferrin (Tf), which is a glycoprotein with a MW of ~80 kDa, has been used as a cancer cell-targeting ligand over several decades (43) and has been clinically tested in the siRNAloaded cyclodextrin nanoparticle (44) . It should be noted that the Tf ligand is also available for active targeting to brain endothelial cells to elicit transcytosis toward the brain parenchyma across the blood-brain barrier (BBB) (45) . In detail, the effect of Tf ligand density on nanoparticles was extensively examined for effective transcytosis across the BBB. Interestingly, the optimized ligand density (or avidity) was observed to cause accumulation of nanoparticles in the brain parenchyma, whereas nanoparticles with a higher density of ligands showed stronger binding to the brain endothelial cellular surface.
Peptide molecules that can be designed with a high selectivity are also promising ligand candidates. For example, a short peptide derived from rabies virus glycoprotein (RVG) (29-mer) is reported to enable the transvascular delivery of siRNA to the brain and specifically bind to the acetylcholine receptor overexpressed on the neuronal cell surface (46) . In addition, the cyclic RGD (arginine-glycine-aspartic acid) peptide (cRGD) has been extensively tested for active targeting of α v β 3 and α v β 5 integrins overexpressed on the surface of various cancer cells and cancerrelated endothelial cells (47) (48) (49) . cRGD-installed mPICs are demonstrated to more efficiently accumulate in subcutaneous tumor models, i.e., α v β 5 -overexpressing cervical cancer cells (HeLa and SiHa cells) and lung cancer cells (A549 cells), compared with non-ligandinstalled mPICs. Ultimately, the cRGD-installed/siRNAloaded mPICs achieved significant antitumor activity against these tumor models by intravenously delivering therapeutic siRNAs targeted to vascular endothelial growth factor (VEGF) and its type-2 receptor (VEGF-R2) in the HeLa model ( Figure 7A ) (34) , papilloma virusderived oncogene E6/E7 in the SiHa model ( Figure 7B ) (36) , and polo-like kinase 1 (PLK1) in the A549 model ( Figure 7C ) (26), associated with sequence-specific gene silencing in the tumor tissues.
An additional important feature of ligand-mediated active targeting is the critical effect of the range of ligand motion on multivalent binding. Although multiple ligand-installed mPICs have a large capacity for multivalent binding to the target molecules, a high density of PEG chains reduces their mobility, as well as the range of ligand motion, because of the steric repulsive (or crowding) effect derived from neighboring PEG chains ( Figure 8A ). This reduction in the PEG mobility and ligand motion makes it difficult to generate effective multivalent binding to target molecules. As an alternative, cocktail PEGylation of nanoparticles with ligand-installed longer PEG and non-ligand-installed shorter PEG demonstrated dramatically enhanced affinity to the target molecule- immobilized surface, presumably due to the enlarged range of ligand motion (or mobility of PEG chains) produced by the spacer effect of shorter PEG fillers for effective multivalent binding ( Figure 8B ) (50).
Polymer design for endosomal escape
Once nucleic acid-loaded nanocarriers are endocytosed by cells, they generally undergo endosomal sorting and ultimately lysosomal degradation. Thus, endosomal escape toward the cytoplasm has been a much-discussed issue in nucleic acid delivery. For enabling endosomal escape of nanocarriers, a major approach is endosomal membrane disruption (or destabilization) using membrane-disrupting polycations or peptides. One of the most widely used polycations is polyethylenimine (PEI). PEI contains low pKa amines, which can protonate in response to the endosomal acidic pH of ~5.5 (51) . This amine protonation is hypothesized to induce the influx of protons and chloride ions into the endosomal compartment, resulting in increased osmotic pressure and ultimately endosome disruption. This is termed the proton sponge effect (52, 53) . Concurrently, amine protonation provides PEI with greater cationic charge, allowing for stronger binding to the negatively charged endosomal membrane and facilitating destabilization (14, 53) .
On the other hand, the considerable cytotoxicity of PEI is always a matter of debate around its pharmaceutical application, and thus, many researchers have focused on reducing its cytotoxicity. Generally, the cytotoxicity of polycations is elicited by cationic charges that allow for nonspecific binding to the cytoplasmic and/or mitochondrial membrane. Therefore, more cationic charges/higher cationic charge densities result in greater cytotoxicity (14, 54, 55) . A typical approach to reduce cytotoxicity is the preparation of biodegradable polycations via intracellularly cleavable bonds, such as disulfide bonds and acid-labile bonds (56, 57) . Low toxicity oligoethylenimines with MW of ~2 kDa have been conjugated with each other via acid-labile imine linkers for preparation of biodegradable PEI, resulting in significantly reduced cytotoxicity associated with a high level of transfection efficiency (56) . Another approach for preparation of low toxic endosomedisrupting polycations is the spatial rearrangement of cationic moieties on the polycation segment for controlled protonation behavior (or cationic charge density). The protonation behavior of the aminoethylene unit, -NHCH 2 CH 2-, which is the repeating unit of PEI, is substantially altered by the repeat number (N R ); increase in N R progressively reduces the change in the protonation degree (Δα) of aminoethylene units between extracellular neutral pH and endosomal acidic pH with a simple harmonic motion ( Figure 9A) (14, 58) . This finding suggests that the aminoethylene unit at N R = 2 possesses higher endosomal pH-responsiveness, compared with the others. When the twice-repeated aminoethylene moieties were introduced into the side chain of polyaspartamide, the obtained polymer, termed PAsp(DET), maintained high Δα (= 0.31), which is significantly higher than that of PEI with a DP of ~500 (Δα = ~0.1) (14, 59) . In detail, the protonation state of side chains in PAsp(DET) is the monoprotonated state with a relatively low cationic charge density at neutral pH, which is distinctly converted to the diprotonated state at endosomal acidic pH ( Figure 9B ). Interestingly, this change in the protonated state of PAsp(DET) was associated with altered membrane disruption (or hemolysis) activity; hemolysis activity was negligible at neutral pH but dramatically elevated at endosomal acidic pH ( Figure 9C ), demonstrating acidic pHresponsive membrane disruptive functionality. Indeed, PAsp(DET) was confirmed to exhibit high transfection efficiency with much lower cytotoxicity, compared with PEI (59) .
As expected, the PEG shell of mPICs considerably compromises endosomal membrane-disruptivity of polycations. Thus, biological environmentresponsiveness is still required to render the nanocarrier surface biologically inert in the extracellular milieu but membrane-active within the endosome. One reasonable approach is PEG-detachable formulations, wherein the PEG segment and the polycation segment are connected via intracellularly cleavable bonds, e.g., disulfide (-SS-) bonds and acid-labile bonds ( Figure  10A ) (60, 61) . In this way, systemic delivery of VEGF siRNA by mPICs prepared from PEG-SS-PAsp(DET) featuring stearoyl moieties in the PAsp(DET) side chains exhibits significant antitumor activity in a subcutaneous pancreatic (BxPC3) tumor model (25) . Another sophisticated approach is the installation of endosome-disrupting polymers onto the mPIC surface (or PEG terminus). In this case, the polycations need additional chemical modifications to mask their cationic charges (or amines). A successful example of aminemasking is the use of amide linkages derived from maleic acid derivatives, including cis-aconitic acid and carboxylated dimethyl maleic acid (CDM), which are relatively stable at neutral pH yet degradable at acidic pH, regenerating the parent amine moiety ( Figure 10B ) (62) (63) (64) . The CDM-modified PAsp(DET) (PAsp(DET-CDM)) was successfully conjugated to the PEG terminus of mPIC through copper-free click chemistry between a dibenzocyclooctyne (DBCO) group and an azide group ( Figure 10B) (35) . The demasking of PAsp(DET-CDM) was verified by an increase in zeta-potential of mPICs at acidic pH, presumably due to the regeneration of cationic PAsp(DET) on the mPIC surface. Ultimately, the PAsp(DET-CDM)-installed mPICs achieved fairly high gene silencing activity in cultured cancer cells, compared with non-installed control mPICs.
Conclusion and perspectives
This review describes the design of polymeric nanocarriers and recent progress regarding their use in small nucleic acid delivery by highlighting methods to overcome biological barriers. To date, many published works have reported excellent therapeutic outcomes in animal disease models. Notably, multifunctional nanocarriers have elicited significant gene silencing mainly in solid tumors as well as the liver, demonstrating their promising therapeutic potential. Nevertheless, there are still limitations or gaps for translation into pharmaceutical products. One of the major reasons for disruption to translation is the limitation of animal disease models, some (or many) of which may not be good surrogates for human patients. Currently, this issue is being actively tackled by many researchers engaged in biology and drug delivery. The establishment of good surrogates can dramatically facilitate the pharmaceutical translation of oligonucleotide therapeutics.
